Irritable Bowel Syndrome Drugs Market Analysis

Type {IBS with Diarrhea (IBS-D), IBS with Constipation (IBS-C), Mixed IBS (IBS-M)}

The global irritable bowel syndrome drugs market is segmented and analyzed for demand and supply by type into IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and mixed IBS (IBS-M). Out of these, the IBS with diarrhea (IBS-D) segment is estimated to gain the largest market share over the projected time frame. The growth of the segment can be attributed to the increasing prevalence of diarrhea among all age groups and the rising adoption of unhealthy lifestyles including the consumption of fast food and alcohol. For instance, diarrheal illnesses are believed to be responsible for 300 annual pediatric fatalities and 167,000 hospitalizations in the US.

Our in-depth analysis of the global irritable bowel syndrome drugs market includes the following segments:

By Type	IBS with Diarrhea (IBS-D) IBS with Constipation (IBS-C) Mixed IBS (IBS-M)
By Product	Xifaxan Linzess Amitiza Viberzi Others
By End User	Drug Stores & Retail Pharmacies Hospital Pharmacies Online Pharmacies

Frequently Asked Questions (FAQ)

Increasing incidences of irritable bowel syndrome and growing availability of over the counter drugs are estimated to boost market growth.

The market is anticipated to attain a CAGR of 14% over the forecast period, i.e., 2023-2035.

Lack of awareness regarding IBS treatment and the side effects of IBS drugs are estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Ardelyx, Inc., Astellas Pharma Inc., AstraZeneca, GlaxoSmithKline Plc, and Johnson & Johnson Services, Inc.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by type, product, end user, and by region.

The IBS with diarrhea (IBS-D) segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

Irritable Bowel Syndrome Drugs Market Analysis